RT @oncology_bg: Later, we updated the meta-analysis with new trial data but the conclusions remained unchanged. https://t.co/Z5iH3Bn6OW @s…
Later, we updated the meta-analysis with new trial data but the conclusions remained unchanged. https://t.co/Z5iH3Bn6OW @sarojniraula
@oncologician @BollamRajesh4 @IJMPOofficial @OncoAlert @VanitaNoronha @SirohiBhawna @sujithonco @VPrasadMDMPH Yup, with @sarojniraula here: https://t.co/ZkeYkxUXzF even with these new data, my conclusions remain unchanged. Non-inferiority lies in the eye
@ndenduluri1 @tmprowell @ASCO @jrgralow @mdmanishshah @aakonc Agree. We have looked at this specific issue (HER2) in a meta-analysis. Selective shorter duration of herceptin might be a consideration as a trade-off with resource constraints. https://t.co/Ut
Whether a noninferiority trial reaches primary endpoint is exclusively based on the definition of non inferiority which is arbitrary. With regards to trastuzumab duration, we need to pool ALL RCTs and not just these 2, which @sarojniraula and I did here: h
RT @oncology_bg: @NicoleKuderer @tmprowell @arkhaki @THilalMD I and @sarojniraula did a meta analysis last year and found the following re…
@NicoleKuderer @tmprowell @arkhaki @THilalMD I and @sarojniraula did a meta analysis last year and found the following results but probably it’s time to update this meta : https://t.co/Z5iH3Bn6OW https://t.co/I0Lw2FSL5y
RT @sarojniraula: @drnirmalraut @ajumathew_ @DrHBurstein @hoperugo We answer this question here: https://t.co/2EtlptFhvR
@drnirmalraut @ajumathew_ @DrHBurstein @hoperugo We answer this question here: https://t.co/2EtlptFhvR
RT @sarojniraula: IPMA would be valuable but difficult. MA based on reported outcomes here: https://t.co/O7WUDBumd6 #BCSM #SABCS18 https://…
RT @sarojniraula: Our meta-analysis https://t.co/O7WUDBumd6 concurs with this statement. 1 year should continue to be the standard, but p…
RT @sarojniraula: Our meta-analysis https://t.co/O7WUDBumd6 concurs with this statement. 1 year should continue to be the standard, but p…
Our meta-analysis https://t.co/O7WUDBumd6 concurs with this statement. 1 year should continue to be the standard, but pts with ER+ and node neg may be spared of the extra Rx mainly in #LMIC and resource/insurance deprived setting within HIC. @oncology_bg
IPMA would be valuable but difficult. MA based on reported outcomes here: https://t.co/O7WUDBumd6 #BCSM #SABCS18
RT @oncology_bg: I'm glad that we are asking similar questions https://t.co/NfgNzSO30f https://t.co/Lf637RaWbz
I'm glad that we are asking similar questions https://t.co/NfgNzSO30f
RT @sarojniraula: Appropriate conclusions by @DrHBurstein In a recent meta-analysis we conclude similarly, but also identify subgroups wher…
RT @sarojniraula: Appropriate conclusions by @DrHBurstein In a recent meta-analysis we conclude similarly, but also identify subgroups wher…
Appropriate conclusions by @DrHBurstein In a recent meta-analysis we conclude similarly, but also identify subgroups where we express lesser confidence about benefits of 1 year, for such sub-groups factors like resource and convenience will be important: h
RT @oncology_bg: Thoughtful editorial by @Otto_DFCI and @DrHBurstein. Agree with this take. Recent meta-analysis supports this conclusion,…
RT @oncology_bg: Thoughtful editorial by @Otto_DFCI and @DrHBurstein. Agree with this take. Recent meta-analysis supports this conclusion,…
Thoughtful editorial by @Otto_DFCI and @DrHBurstein. Agree with this take. Recent meta-analysis supports this conclusion, although subgroup analysis suggested that for node negative and hormone positive patients, shorter duration may be enough. https://t.c
RT @oncology_bg: @SirohiBhawna @NagiSaghir Actually, @sarojniraula and I did a meta-analysis including persophene and found that 1yr of the…
RT @oncology_bg: One of the very important questions in breast oncology answered by @sarojniraula : is shorter duration of adjuvant trastuz…
One of the very important questions in breast oncology answered by @sarojniraula : is shorter duration of adjuvant trastuzumab enough for her2+ early breast cancer? Unfortunately, despite Persephone, the answer seems "we can't say that yet". https://t.co/N
RT @oncology_bg: @SirohiBhawna @NagiSaghir Actually, @sarojniraula and I did a meta-analysis including persophene and found that 1yr of the…
@SirohiBhawna @NagiSaghir Actually, @sarojniraula and I did a meta-analysis including persophene and found that 1yr of therapy continued to improve outcomes. Opposite to what we thought we'd find, but probably not enough data yet to support shorter duratio
RT @Senology: Best Sudy of the Day: Trastuzumab in Early Breast Cancer https://t.co/h9mYIE2VBd - Breast Cancer Research and Treatment - #br…
RT @Senology: Best Sudy of the Day: Trastuzumab in Early Breast Cancer https://t.co/h9mYIE2VBd - Breast Cancer Research and Treatment - #br…
RT @Senology: Best Sudy of the Day: Trastuzumab in Early Breast Cancer https://t.co/h9mYIE2VBd - Breast Cancer Research and Treatment - #br…
Best Sudy of the Day: Trastuzumab in Early Breast Cancer https://t.co/h9mYIE2VBd - Breast Cancer Research and Treatment - #breast #cancer #trastuzumab #seno #mammella #tumori
RT @sarojniraula: Meta-analysis post Persephone on herceptin duration is out: One year still superior to shorter Rx in overall population…
RT @sarojniraula: Meta-analysis post Persephone on herceptin duration is out: One year still superior to shorter Rx in overall population…
RT @sarojniraula: Meta-analysis post Persephone on herceptin duration is out: One year still superior to shorter Rx in overall population…
RT @sarojniraula: Meta-analysis post Persephone on herceptin duration is out: One year still superior to shorter Rx in overall population…
RT @sarojniraula: Meta-analysis post Persephone on herceptin duration is out: One year still superior to shorter Rx in overall population…
RT @sarojniraula: Meta-analysis post Persephone on herceptin duration is out: One year still superior to shorter Rx in overall population…
RT @sarojniraula: Meta-analysis post Persephone on herceptin duration is out: One year still superior to shorter Rx in overall population…
Meta-analysis post Persephone on herceptin duration is out: One year still superior to shorter Rx in overall population (unfortunately) but the benefits of longer Rx are more convincing in node pos and ER neg. https://t.co/O7WUDBumd6 https://t.co/hisMSOq
Optimal duration of adjuvant #Trastuzumab in treatment of early #BreastCancer https://t.co/BnC9rUl9sk @BCRJournal #ECM https://t.co/zm4CdCX9D6